MIC12

MIC12 is a novel, target-restricted immunocytokine developed for the treatment of acute myeloid leukemia (AML). It consists of a humanized monoclonal antibody targeting CLEC12A (CLL-1) with an Fc-optimized domain (containing S239D and I332E mutations, known as SDIE) fused to a modified interleukin-15 (IL-15) moiety. The IL-15 component features an E46K mutation that abrogates its binding to the IL-15Rα chain, thereby ensuring that its stimulatory activity is conditionally activated only upon binding to the CLEC12A antigen on target cells. This design allows for the localized stimulation of IL-15Rβ/γ-expressing effector cells, such as natural killer (NK) cells, while minimizing systemic off-target toxicity. Developed through a collaboration between ABL Bio and the University of Tübingen, MIC12 has demonstrated superior NK cell activation, proliferation, and anti-leukemic efficacy in preclinical models compared to standard Fc-optimized antibodies.

Other names

CLEC12A-directed immunocytokineCLEC-12A-directed immunocytokineCLEC 12A-directed immunocytokineanti-CLEC12A IL-15 immunocytokineanti-CLEC-12A IL-15 immunocytokineanti-CLEC 12A IL-15 immunocytokineCLL-1-directed immunocytokineCLL1-directed immunocytokineCLL 1-directed immunocytokine